» Articles » PMID: 9053841

Molecular Characterization of ALK, a Receptor Tyrosine Kinase Expressed Specifically in the Nervous System

Overview
Journal Oncogene
Date 1997 Jan 30
PMID 9053841
Citations 263
Authors
Affiliations
Soon will be listed here.
Abstract

The 2;5 chromosomal translocation is frequently associated with anaplastic large cell lymphomas (ALCLs). The translocation creates a fusion gene consisting of the alk (anaplastic lymphoma kinase) gene and the nucelophosmin (npm) gene: the 3' half of alk derived from chromosome 2 is fused to the 5' portion of npm from chromosome 5. A recent study shows that the product of the npm-alk fusion gene is oncogenic. To help understand how the npm-alk oncogene transform cells, it is important to investigate the normal biological function of the alk gene product, ALK. Here, we show molecular cloning of cDNAs for both the human and mouse ALK proteins. The deduced amino acid sequences reveal that ALK is a novel receptor protein-tyrosine kinase having a putative transmembrane domain and an extracellular domain. These sequences are absent in the product of the transforming npm-alk gene. ALK shows the greatest sequence similarity to LTK (leukocyte tyrosine kinase) whose biological function is presently unknown. RNA blot hybridization analysis of various tissues reveals that the alk mRNA is dominantly detected in the brain and spinal cord. Immunoblotting with anti-ALK antibody shows that ALK is highly expressed in the neonatal brain. Furthermore, RNA in situ hybridization analysis shows that the alk mRNA is dominantly expressed in neurons in specific regions of the nervous system such as the thalamus, mid-brain, olfactory bulb, and ganglia of embryonic and neonatal mice. These data suggest that ALK plays an important role(s) in the development of the brain and exerts its effects on specific neurons in the nervous system.

Citing Articles

3D genomic features across >50 diverse cell types reveal insights into the genomic architecture of childhood obesity.

Trang K, Pahl M, Pippin J, Su C, Littleton S, Sharma P Elife. 2025; 13.

PMID: 39813287 PMC: 11735026. DOI: 10.7554/eLife.95411.


A New Approach of Detecting Fusion Oncogenes by RNA Sequencing Exon Coverage Analysis.

Zakharova G, Suntsova M, Rabushko E, Mohammad T, Drobyshev A, Seryakov A Cancers (Basel). 2024; 16(22).

PMID: 39594806 PMC: 11592821. DOI: 10.3390/cancers16223851.


The Use of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer Treatment-Literature Review.

Gorzelak-Magiera A, Domagala-Haduch M, Kabut J, Gisterek-Grocholska I Biomedicines. 2024; 12(10).

PMID: 39457620 PMC: 11504905. DOI: 10.3390/biomedicines12102308.


Revisiting ALK (D5F3) immunohistochemistry: Insights into focal staining and neuroendocrine differentiation.

Sung Y, Kim M Thorac Cancer. 2024; 15(30):2175-2184.

PMID: 39257160 PMC: 11496193. DOI: 10.1111/1759-7714.15445.


Natural product-derived ALK inhibitors for treating ALK-driven lung cancers: an in silico study.

Alshammari S, Alshammari Q Mol Divers. 2024; .

PMID: 39115579 DOI: 10.1007/s11030-024-10953-2.